Who is sponsoring NCT03997136?

NCT03997136 is sponsored by Assiut University.

What drugs are being tested in NCT03997136?

Interventions in NCT03997136: Supratentorial high grade gliomas resection..

What condition does NCT03997136 study?

NCT03997136 studies Supratentorial Glioblastoma.

Is NCT03997136 still recruiting?

NCT03997136 is currently status unknown. Last updated 7 August 2019.

Last reviewed 2019-08-07 · How we verify

NCT03997136

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prognostic Impact of Surgical Resection Extent for Supratentorial High Grade Gliomas.

Status unknown Last updated 7 August 2019

What this trial tests

trial testing Supratentorial high grade gliomas resection. in Supratentorial Glioblastoma in 28 participants. Status unknown.

Timeline

1 September 2019

Primary endpoint
1 April 2021

1 July 2021

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	28
Start date	1 September 2019
Primary completion	1 April 2021
Estimated completion	1 July 2021

Drugs / interventions tested

Supratentorial high grade gliomas resection.

Conditions studied

Supratentorial Glioblastoma — all drugs for Supratentorial Glioblastoma →

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Supratentorial Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective randomized controlled clinical trials (single arm study) of surgical treatment modalities for supratentorial high grade gliomas within the next two years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Supratentorial Glioblastoma

Currently open trials in the same condition.

NCT05052957 — hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) · Phase 2 · recruiting
NCT03197506 — Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma · Phase 2 · active not recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03997136 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 7 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03997136.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing